1. Home
  2. SLXN vs CHEK Comparison

SLXN vs CHEK Comparison

Compare SLXN & CHEK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SLXN
  • CHEK
  • Stock Information
  • Founded
  • SLXN 2008
  • CHEK 2004
  • Country
  • SLXN Israel
  • CHEK Israel
  • Employees
  • SLXN N/A
  • CHEK N/A
  • Industry
  • SLXN
  • CHEK Medical Electronics
  • Sector
  • SLXN
  • CHEK Health Care
  • Exchange
  • SLXN NYSE
  • CHEK Nasdaq
  • Market Cap
  • SLXN 7.6M
  • CHEK 9.0M
  • IPO Year
  • SLXN N/A
  • CHEK 2015
  • Fundamental
  • Price
  • SLXN $1.38
  • CHEK $0.90
  • Analyst Decision
  • SLXN Strong Buy
  • CHEK
  • Analyst Count
  • SLXN 1
  • CHEK 0
  • Target Price
  • SLXN $9.00
  • CHEK N/A
  • AVG Volume (30 Days)
  • SLXN 31.6M
  • CHEK 95.8K
  • Earning Date
  • SLXN 02-21-2025
  • CHEK 02-18-2025
  • Dividend Yield
  • SLXN N/A
  • CHEK N/A
  • EPS Growth
  • SLXN N/A
  • CHEK N/A
  • EPS
  • SLXN N/A
  • CHEK N/A
  • Revenue
  • SLXN N/A
  • CHEK N/A
  • Revenue This Year
  • SLXN N/A
  • CHEK N/A
  • Revenue Next Year
  • SLXN N/A
  • CHEK N/A
  • P/E Ratio
  • SLXN N/A
  • CHEK N/A
  • Revenue Growth
  • SLXN N/A
  • CHEK N/A
  • 52 Week Low
  • SLXN $0.21
  • CHEK $0.56
  • 52 Week High
  • SLXN $13.56
  • CHEK $3.45
  • Technical
  • Relative Strength Index (RSI)
  • SLXN N/A
  • CHEK 42.16
  • Support Level
  • SLXN N/A
  • CHEK $0.81
  • Resistance Level
  • SLXN N/A
  • CHEK $1.00
  • Average True Range (ATR)
  • SLXN 0.00
  • CHEK 0.10
  • MACD
  • SLXN 0.00
  • CHEK -0.05
  • Stochastic Oscillator
  • SLXN 0.00
  • CHEK 13.98

About SLXN BIOMOTION SCIENCES

Silexion Therapeutics Corp is a developmental-stage company dedicated to the development of treatments for pancreatic cancer. The company is focused on enhancing its first-generation product (LODERTM ) to develop a newly formulated product to improve the clinical efficacy against pancreatic cancer.

About CHEK Check-Cap Ltd.

Check-Cap Ltd is a clinical-stage medical diagnostics company engaged in the development of an ingestible imaging capsule that utilizes low-dose X-rays for the detection and imaging of colonic polyps and colorectal cancers, or CRC. The company is developing C-Scan, the first capsule-based system for preparation-free, colorectal cancer screening. Its scanning capsule will be swallowed and propelled by natural motility through the gastrointestinal tract and excreted naturally with no need for retrieval for data collection. The operations of the company are presently located in Israel, but it currently expects to market products in the United States, Europe, Israel and Japan.

Share on Social Networks: